静脉血栓患者吃利伐沙班需要吃多长时间？

It has a preventive effect on deep vein thrombosis that occurs after hip or knee replacement surgery, and it can also prevent pulmonary embolism that occurs after hip or knee replacement surgery. How long should patients with venous thrombosis take rivaroxaban?

The duration of taking rivaroxaban varies from person to person, please consult your doctor for details!

How to take rivaroxaban:

1. Oral administration: Rivaroxaban 10 mg can be taken with food or alone.

Rivaroxaban 15 mg or 20 mg tablets should be taken with food.

2. To prevent venous thrombosis in adult patients undergoing elective hip or knee replacement surgery:

The recommended dose is rivaroxaban 10 mg orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery.

3. For patients undergoing major hip surgery, the recommended treatment course is 35 days.

4. For patients undergoing major knee surgery, the recommended treatment course is 12 days.

5. If a missed dose occurs, the patient should take rivaroxaban immediately and continue to take the medicine once a day the next day.

6. Treat DVT and reduce the risk of acute DVT recurrence and PE.

The recommended dose for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent DVT and PE.

7. If a missed dose occurs during 15 mg twice daily treatment (days 1-21), the patient should take rivaroxaban immediately to ensure that 30 mg of rivaroxaban is taken daily. In this case, it may be necessary to take two 15 mg tablets at once. Thereafter, regular 15 mg twice daily dosing should be continued as recommended.

8. If a missed dose occurs during 20 mg once-daily treatment (day 22 and thereafter), the patient should take it immediately and continue to receive once-daily dosing at the recommended dose thereafter. The dose should not be doubled in one day to make up for a missed dose.

Recommended related hot articles: /newsDetail/79785.html